$Akoustis Technologies (AKTS.US)$ was supposed to be open before market open, seems very positive.
2
1
$T2 Biosystems (TTOO.US)$ I'd be sad as wealthsimple paused any trades for this stock:/
scooobydoo
commented on
Hello Mooers,
The top 5 stocks with the highest short volume are listed here, with their short volume next to it.
MTNB $Matinas BioPharma (MTNB.US)$ (43.64M)
TPST $Tempest Therapeutics (TPST.US)$ (17.55M)
PLUG $Plug Power (PLUG.US)$ (15.41M)
XOM $Exxon Mobil (XOM.US)$ (13.43M)
AVTX $Avalo Therapeutics (AVTX.US)$ (13.06M)
So, which of the stocks listed above will you be trading in the next 7 days?
(You may choose more than 1.)
The ...
The top 5 stocks with the highest short volume are listed here, with their short volume next to it.
MTNB $Matinas BioPharma (MTNB.US)$ (43.64M)
TPST $Tempest Therapeutics (TPST.US)$ (17.55M)
PLUG $Plug Power (PLUG.US)$ (15.41M)
XOM $Exxon Mobil (XOM.US)$ (13.43M)
AVTX $Avalo Therapeutics (AVTX.US)$ (13.06M)
So, which of the stocks listed above will you be trading in the next 7 days?
(You may choose more than 1.)
The ...
13
2
scooobydoo
commented on
$T2 Biosystems (TTOO.US)$
1) Strengthened balance sheet by converting $10 million in CRG debt to equity
2) Sales do NOT include BARDA (since T2 received the FDA clearance for the Biothreat panel)
3) Large shortfall due to backorders (Hence why they are ramping up development by hiring new people)
4) Expecting Q4 to be far more productive with fulfilling backorders and new sales
5) Products take time to develop to meet demand
6) Shifted focus on supply ch...
1) Strengthened balance sheet by converting $10 million in CRG debt to equity
2) Sales do NOT include BARDA (since T2 received the FDA clearance for the Biothreat panel)
3) Large shortfall due to backorders (Hence why they are ramping up development by hiring new people)
4) Expecting Q4 to be far more productive with fulfilling backorders and new sales
5) Products take time to develop to meet demand
6) Shifted focus on supply ch...
2
3